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Background & aims: The investigation was done to assess the impacts of probiotic supplementation on
movement and metabolic parameters in individuals with Parkinson's disease (PD).
Methods: The study is randomized, double-blind, placebo-controlled clinical trial, which was done in
sixty people with PD. Individuals were randomly divided into two groups in order to take either
8  109 CFU/day probiotic or placebo (n ¼ 30 each group) that lasted 12 weeks. The Movement Disorders
Society-Uniﬁed Parkinson's Disease Rating Scale (MDS-UPDRS) was recorded at pre- and post-
intervention.
Results: Compared with the placebo, consuming probiotic decreased MDS-UPDRS (4.8 ± 12.5
vs. þ3.8 ± 13.0, P ¼ 0.01). Probiotic supplementation also reduced high-sensitivity C-reactive protein
(1.6 ± 2.5 vs. þ0.1 ± 0.3 mg/L, P < 0.001) and malondialdehyde (0.2 ± 0.3 vs. þ0.1 ± 0.3 mmol/L,
P ¼ 0.006), and enhanced glutathione levels (þ40.1 ± 81.5 vs. 12.1 ± 41.7 mmol/L, P ¼ 0.03) in com-
parison with the placebo. Additionally, probiotic consumption resulted in a statistically signiﬁcant
reduction in insulin levels (2.1 ± 3.4 vs. þ1.5 ± 5.1 mIU/mL, P ¼ 0.002) and insulin resistance (0.5 ± 0.9
vs. þ0.4 ± 1.2, P ¼ 0.002), and a statistically signiﬁcant rise in insulin sensitivity (þ0.01 ± 0.02
vs. 0.006 ± 0.02, P ¼ 0.01) in comparison with the placebo. Probiotic intake had no any signiﬁcant
impact on other metabolic proﬁles.
Conclusions: Our study evidenced that 12 weeks of probiotic consumption by individuals with PD had
useful impacts on MDS-UPDRS and few metabolic proﬁles. Registered under ClinicalTrials.gov Identiﬁer
no. http://www.irct.ir: IRCT2017082434497N4.
© 2018 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.1. Introduction
Parkinson's disease (PD) is a neuropsychiatric disturbance that
inﬂuences up to two percent of people older [1] and reported a
prevalence of 14 per 100,000 subjects [2]. Approximately, 40% of PD
people present cognitive disorders [3]. Various factors such as
increased production of free radicals and oxidative damage,for Clinical Nutrition and Metabol
R, et al., Clinical and metabo
o-controlled trial, Clinical Numitochondrial dysfunction, excitotoxicity, increased inﬂammatory
cytokines, genetic factors, environmental factors, and apoptosis in
neuronal degeneration of PD have been proposed [4]. In addition,
data from epidemiological studies reported that more than 50% of
people with PD have impaired carbohydrate metabolism [5],
however data from prospective studies suggest the association is
more modest with type 2 diabetes mellitus subjects having
approximately a 40% elevated risk of developing PD [6].
Animal studies have reported a disturbed gutmicrobiota (GM) in
a number of central nervous system disturbances, such as PD and
multiple sclerosis (MS); data from human studies is little andism. All rights reserved.
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functions related to bloodebrain barrier may be associated with
neurodegenerative disorders [8]. GM can affect various neurological
outcomes, such as cognition, learning, and memory [9]. Earlier,
some researchers have exhibited that probiotics are beneﬁt on
clinical and metabolic parameters in neurodegenerative disorders.
The authors have previously demonstrated that 12 weeks of pro-
biotic consumption by individuals with MS had beneﬁcial impacts
on clinical signs, mental health, insulin resistance and markers of
cardio-metabolic risk [10]. The intake of synbiotic milk was beneﬁt
in improving constipation in peoplewith PD [11].Moreover, ameta-
analysis study supported probiotic intake is effective in reducing
lipid values and factors related to cardiovascular disease [12].
Considering the antioxidant and anti-inﬂammatory effects of
probiotic, we assumed that probiotic might be useful in patients
with PD. Therefore, this investigation was done to deﬁne the im-
pacts of probiotic supplementation on clinical and biochemical
proﬁles in people with PD.
2. Subjects and methods
2.1. Trial design and participants
This study was a 12-week randomized, double-blinded, pla-
cebo-controlled clinical trial, which was registered with the web-
site for registration of clinical trials in Iran (http://www.irct.ir:
IRCT2017082434497N4). Sixty individuals with PD, aged 50e90
years, which were diagnosed in accordance with the UK PD Society
Brain Bank clinical diagnostic criteria [13] were included in this
trial. The study was carried out from August to December 2017 and
study protocol was conﬁrmed by the Kashan University of Medical
Sciences (KAUMS) Research Ethics Committee. Signed informed
consent was taken from all patients. The exclusion criteria were as
follows: taking antioxidants supplements and anti-inﬂammatory
medications, depression and severe psychosis, hypo- and hyper-
thyroidism, and smoking.
2.2. Study design
First, all patients were randomized into two treatment groups to
intake probiotic containing Lactobacillus acidophilus, Biﬁdobacte-
riumbiﬁdum, Lactobacillus reuteri, and Lactobacillus fermentum (each
2 109 CFU/g) (n¼ 30) or placebo (n¼ 30) for 12 weeks. Probiotics
and its placebos were produced by Lactocare Zisttakhmir Company
(Tehran, Iran) and Barij Essence Pharmaceutical Company (Kashan,
Iran), respectively. Capsules had similar packaging. Randomization
assignment was done using computer-generated random numbers
as blindness by a trained staff at the neurology clinic. Patients, in-
vestigators, clinical site staff and laboratory staff were all masked to
treatment assignment throughout the study. Compliance rate was
assessed counting the remaining supplements.
2.3. Assessment of outcomes
In this study, Movement Disorders Society-Uniﬁed Parkinson's
Disease Rating Scale (MDS-UPDRS) and high-sensitivity C-reactive
protein (hs-CRP) were considered as the primarymeasurement and
other metabolic proﬁles were considered as the secondary
measurements.
2.4. Clinical evaluation
To evaluate clinical signs, UPDRS total score as well as 4 sub-
scores were used [14].Please cite this article in press as: Tamtaji OR, et al., Clinical and metab
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Fasting blood samples (10 mL) were collected at weeks 0 and
12 at Kashan Reference Laboratory, Kashan, Iran. Hs-CRP (LDN,
Nordhorn, Germany) and insulin (Monobind, California, USA) levels
were measured using an ELISA kit. Plasma total antioxidant ca-
pacity (TAC) using the method of Benzie and Strain [15], GSH by the
method of Beutler et al. [16] and malondialdehyde (MDA) levels
using the spectrophotometric method were evaluated. In order to
determine fasting plasma glucose (FPG) and lipid proﬁles, we used
available kits (Pars Azmun, Tehran, Iran) Homeostasis model of
assessment-estimated insulin resistance (HOMA-IR) and the
quantitative insulin sensitivity check index (QUICKI) were calcu-
lated according to suggested formulas. Inter- and intra-assay co-
efﬁcient variances (CVs) for metabolic proﬁles were lower than 5%.
2.6. Sample size
In order to have the power of study at 80%, type one (a) and type
two errors (b) were considered to be 0.05, and 0.20. We used
2.8 mg/L as mean difference (d) for hs-CRP and 3.5 mg/L as the SD,
using a similar study published by Kouchaki et al. [10]. Thereupon,
25 subjects should be recruited in each treatment group. Consid-
ering 20% dropouts in each group; the ﬁnal sample size was
calculated to be 30 participants in each group.
2.7. Statistical methods
Thenormality testswere conducted usingKolmogoroveSmirnov
test. Anthropometric indices anddietary intakes (macro- andmicro-
nutrients) were compared between intervention groups, using in-
dependent samples t-test. One-way repeated measures analysis of
variance was applied to determine the effects of probiotic supple-
mentation on clinical signs of the disease and patients' metabolic
proﬁles. Differences in baseline values, including age and BMI, were
adjusted using analysis of covariance (ANCOVA). Signiﬁcant levels
were deﬁned as P-values <0.05.
3. Results
Six participants dropped during follow-up, due to personal
reasons, four in the supplemented and 2 in the placebo groups
(Fig. 1). However, using ITT analyses, all sixty individuals were
included in the ﬁnal analysis. Above 90% of capsules were used
during intervention in case and control groups leading to high
compliance rate in this study. Probiotic supplementation in PD
patients did not result in any reported side effects.
Mean age and anthropometric indices at baseline and end of
trial were not statistically different between the case and control
groups (Table 1).
We didn't ﬁnd signiﬁcant change in mean dietary intakes be-
tween the case and control groups throughout the trial (Data not
shown).
Consuming probiotic decreased MDS-UPDRS (4.8 ± 12.5
vs. þ3.8 ± 13.0, P ¼ 0.01) (Table 2). Probiotic consumption also
reduced hs-CRP (1.6 ± 2.5 vs.þ0.1 ± 0.3 mg/L, P < 0.001) andMDA
(0.2 ± 0.3 vs. þ0.1 ± 0.3 mmol/L, P ¼ 0.006), and increased GSH
levels (þ40.1 ± 81.5 vs.12.1 ± 41.7 mmol/L, P¼ 0.03) in comparison
with the placebo. Additionally, probiotic intake decreased insulin
levels (2.1 ± 3.4 vs. þ1.5 ± 5.1 mIU/mL, P ¼ 0.002) and HOMA-IR
(0.5 ± 0.9 vs. þ0.4 ± 1.2, P ¼ 0.002), and elevated QUICKI
(þ0.01 ± 0.02 vs. 0.006 ± 0.02, P ¼ 0.01). In addition, a trend
toward a greater decrease in triglycerides (19.7 ± 53.5
vs. þ0.4 ± 21.5, P ¼ 0.06) and VLDL-cholesterol levels (3.9 ± 10.7
vs. þ0.1 ± 4.3, P ¼ 0.06) was observed after probiotic intake.olic response to probiotic administration in people with Parkinson's
trition (2018), https://doi.org/10.1016/j.clnu.2018.05.018
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Fig. 1. Summary of patient ﬂow.
Table 1
General characteristics of study participants.
Placebo group
(n ¼ 30)
Probiotic group
(n ¼ 30)
Pa
Age (y) 67.7 ± 10.2 68.2 ± 7.8 0.83
Height (cm) 164.8 ± 6.0 164.2 ± 5.3 0.69
Weight at study baseline (kg) 70.0 ± 10.0 71.6 ± 8.6 0.49
Weight at end-of-trial (kg) 69.9 ± 9.0 72.0 ± 8.5 0.37
Weight change (kg) 0.1 ± 0.8 0.4 ± 1.1 0.07
BMI at study baseline (kg/m2) 25.8 ± 3.5 26.6 ± 3.2 0.36
BMI at end-of-trial (kg/m2) 25.7 ± 3.5 26.7 ± 3.1 0.26
BMI change (kg/m2) 0.1 ± 0.3 0.1 ± 0.4 0.07
Data are means ± SDs.
a Obtained from independent t-test.
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metabolic proﬁles.
After controlling for potential confounders, the difference in
changes in MDA (P ¼ 0.12) between the two groups became non-
signiﬁcant, while difference in changes in triglycerides (P ¼ 0.04)
and VLDL-cholesterol (P ¼ 0.04) (Table 3).
4. Discussion
In this investigation, we determined the effect of consuming
probiotic on movement and metabolic parameters in people with
PD. We realized that taking probiotic for 12 weeks by people with
PD had favorable impacts on MDS-UPDRS, hs-CRP, GSH, MDA and
insulin metabolism, but did not affect other metabolic parameters.
This investigation is the ﬁrst report of the impacts of probiotic
consumption on movement and metabolic parameters in people
with PD.
4.1. Effects on clinical signs and inﬂammation and oxidative stress
We demonstrated that taking probiotic reduced MDS-UPDRS,
hs-CRP and MDA, and elevated GSH levels, although unchanged
TAC. There is growing evidence that probiotic supplementation
can considerably modulate gut microbiota, therefore representing
important assets in the management of oxidative damage. Earlier,
we have demonstrated that probiotic consumption for 12 weeks to
Alzheimer's disease subjects was beneﬁt in improving cognitive
function, hs-CRP, MDA, but unaltered TAC and GSH [17]. In addition,
supplementation with probiotic for 48 weeks to human immuno-
deﬁciency virus-infected people signiﬁcantly decreased CRP levels
[18]. In another study, synbiotic administration to obese children
for 4 weeks improved cardio-metabolic risk [19]. It has conﬁrmed
that increased oxidative damage and the inﬂammatory response
occur in the severity of PD and these factors contribute to and/orPlease cite this article in press as: Tamtaji OR, et al., Clinical and metabo
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capable of producing potential antioxidants and bioactive mole-
cules, thus are capable to decrease free radicals and oxidative stress
[9]. In addition, probiotics can produce gamma-aminobutyric acid,
noradrenaline, serotonin and acetylcholine, which in turn affect
central neurochemistry and behavior [20]. Probiotics intake may
improve clinical signs via the inhibiting indoleamine 2,3-
dioxygenase and inﬂammatory factors such as interferon gamma
and interleukin-6 (IL-6) [21]. Also, probioticsmight improve hs-CRP
and oxidative stress through the increased production of short
chain fatty acids (SCFA) in the gut [22]. SCFA may decrease hs-CRP
values through suppressing the enzymatic synthesis of hepatic CRP
[23]. Hegazy et al. [24] demonstrated that taking probiotic by
people with ulcerative colitis for 8 weeks decreased inﬂammation
by reducing levels of IL-6, and gene expression of tumor necrosis
factor-alpha and nuclear factor kappa B.4.2. Effects on insulin metabolism and lipid proﬁles
This study conﬁrmed that probiotic supplementation reduced
insulin concentrations, HOMA-IR and QUICKI, however, unchangedlic response to probiotic administration in people with Parkinson's
trition (2018), https://doi.org/10.1016/j.clnu.2018.05.018
Table 2
Uniﬁed Parkinson's disease rating stage, biomarkers of inﬂammation and oxidative stress, and metabolic proﬁles at baseline and after the 12-week intervention in people with
Parkinson's disease that received either probiotic or placebo.
Placebo group (n ¼ 30) Probiotic group (n ¼ 30) P1
Baseline End-of-trial Change Baseline End-of-trial Change
MDS-UPDRS total (0e195) 60.0 ± 37.5 63.8 ± 35.4 3.8 ± 13.0 76.2 ± 37.2 71.5 ± 35.3 4.8 ± 12.5 0.01
hs-CRP (mg/L) 4.4 ± 2.5 4.5 ± 2.4 0.1 ± 0.3 5.3 ± 3.0 3.7 ± 1.4 1.6 ± 2.5 <0.001
TAC (mmol/L) 818.8 ± 216.5 823.4 ± 213.5 4.5 ± 26.7 826.3 ± 88.7 842.6 ± 79.1 16.3 ± 49.6 0.25
GSH (mmol/L) 566.6 ± 120.9 554.5 ± 107.1 12.1 ± 41.7 493.6 ± 85.4 533.7 ± 89.9 40.1 ± 81.5 0.03
MDA (mmol/L) 2.4 ± 0.4 2.5 ± 0.4 0.1 ± 0.3 2.7 ± 0.3 2.5 ± 0.2 0.2 ± 0.3 0.006
FPG (mg/dL) 98.5 ± 19.2 96.4 ± 23.9 2.0 ± 12.7 105.3 ± 16.4 98.5 ± 16.9 6.8 ± 12.1 0.14
Insulin (mIU/mL) 11.0 ± 4.8 12.6 ± 4.5 1.5 ± 5.1 12.3 ± 5.9 10.2 ± 5.1 2.1 ± 3.4 0.002
HOMA-IR 2.7 ± 1.4 3.1 ± 1.3 0.4 ± 1.2 3.2 ± 1.7 2.7 ± 1.4 0.5 ± 0.9 0.002
QUICKI 0.33 ± 0.02 0.33 ± 0.03 0.006 ± 0.02 0.33 ± 0.03 0.34 ± 0.04 0.01 ± 0.02 0.01
Triglycerides (mg/dL) 138.1 ± 52.9 138.5 ± 58.1 0.4 ± 21.5 140.5 ± 50.0 120.8 ± 41.2 19.7 ± 53.5 0.06
VLDL-cholesterol (mg/dL) 27.6 ± 10.6 27.7 ± 11.6 0.1 ± 4.3 28.1 ± 10.0 24.1 ± 8.2 3.9 ± 10.7 0.06
Total cholesterol (mg/dL) 180.9 ± 39.3 178.8 ± 41.3 2.1 ± 26.0 183.3 ± 39.1 182.2 ± 45.1 1.1 ± 43.5 0.90
LDL-cholesterol (mg/dL) 109.5 ± 30.3 106.7 ± 32.6 2.8 ± 23.9 106.9 ± 34.2 109.2 ± 38.1 2.3 ± 40.4 0.55
HDL-cholesterol (mg/dL) 43.8 ± 11.5 44.4 ± 11.6 0.6 ± 4.6 48.2 ± 10.1 48.7 ± 9.5 0.5 ± 7.9 0.98
Data are means ± SDs.
1P values represent the time  group interaction (computed by analysis of the one-way repeated measures ANOVA).
FPG, fasting plasma glucose; GSH, total glutathione; HOMA-IR, homeostasis model of assessment-estimated insulin resistance; hs-CRP, high-sensitivity C-reactive protein;
MDS-UPDRS, Movement Disorders Society-Uniﬁed Parkinson's Disease Rating Scale; MDA, malondialdehyde; QUICKI, quantitative insulin sensitivity check index; TAC, total
antioxidant capacity; UPDRS, uniﬁed Parkinson's disease rating stage.
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tigated the impacts of the supplementation of probiotic on glyce-
mic status and lipid fractions in people with metabolic diseases.
Earlier, we showed that probiotic supplementation for 12 weeks to
people with diabetic foot ulcer was beneﬁt on glycemic status and
total cholesterol levels, but unaltered lipid proﬁles [25]. Also, 12
weeks of probiotic administration by people with non-alcoholic
fatty liver disease showed a beneﬁcial impact on insulin meta-
bolism, but did not inﬂuence fasting glucose [26]. In a meta-
analysis investigation, receiving probiotic by women with gesta-
tional diabetes signiﬁcantly reduced HOMA-IR, although un-
changed fasting glucose and LDL-cholesterol levels [27]. Changes in
glucose homeostasis parameters correlated with loss of dopami-
nergic function might happen in people with PD, which may result
in increased comorbidity andmortality [6]. Therefore, PD treatmentTable 3
Adjusted changes in uniﬁed Parkinson's disease rating stage, biomarkers of
inﬂammation and oxidative stress, and metabolic proﬁles in patients with Par-
kinson's disease that received either probiotic or placeboa.
Placebo group
(n ¼ 30)
Probiotic group
(n ¼ 30)
Pb
MDS-UPDRS total (0e195) 3.1 ± 2.2 4.1 ± 2.2 0.03
hs-CRP (mg/L) 0.03 ± 0.2 1.4 ± 0.2 <0.001
TAC (mmol/L) 4.4 ± 7.3 16.5 ± 7.3 0.24
GSH (mmol/L) 3.5 ± 10.8 31.5 ± 10.8 0.03
MDA (mmol/L) 0.02 ± 0.04 0.1 ± 0.04 0.12
FPG (mg/dL) 2.2 ± 2.3 6.6 ± 2.3 0.19
Insulin (mIU/mL) 1.3 ± 0.7 1.8 ± 0.7 0.003
HOMA-IR 1.3 ± 0.7 1.8 ± 0.7 0.003
QUICKI 0.006 ± 0.005 0.01 ± 0.005 0.01
Triglycerides (mg/dL) 0.3 ± 6.8 19.6 ± 6.8 0.04
VLDL-cholesterol (mg/dL) 0.1 ± 1.4 3.9 ± 1.4 0.04
Total cholesterol (mg/dL) 2.0 ± 6.3 1.3 ± 6.3 0.93
LDL-cholesterol (mg/dL) 1.6 ± 5.6 1.1 ± 5.6 0.73
HDL-cholesterol (mg/dL) 0.1 ± 1.1 1.0 ± 1.1 0.58
a All values are means ± SEs.
b Obtained from analysis of ANCOVA adjusted for baseline values þ age and
baseline BMI. FPG, fasting plasma glucose; GSH, total glutathione; HOMA-IR, ho-
meostasis model of assessment-estimated insulin resistance; hs-CRP, high-
sensitivity C-reactive protein; MDA, malondialdehyde; QUICKI, quantitative in-
sulin sensitivity check index; TAC, total antioxidant capacity; UPDRS, uniﬁed
Parkinson's disease rating stage.
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cations related to PD. This difference in the results of various
studies could be correlated with the differences in the kind of
studied diseases, composition of the basal microbiota population,
type of probiotic supplements and dosage of probiotic used, basic
concentrations of glycemic and lipid parameters and duration of
the intervention. Probiotic may beneﬁt in improving the insulin
resistance through reducing the concentration of endotoxin,
increasing fecal PH and increasing production of SCFA in the gut,
and decreasing the production and absorption of intestinal toxins
[28]. In addition, probiotics may increase glucagon-like peptide 1
production from enteroendocrine L-cells to ameliorate carbohy-
drate metabolism, reduce glucotoxicity, and decrease insulin
resistance in target cells [29]. Probiotic intake also inﬂuences the
structure of the gut ﬂora, which might reclaim the integrity of the
intestinal epithelium, weaken the immune responses, and decrease
the Toll-like receptor 4 pathways [30], which in turn reduces pro-
inﬂammatory signaling and increases insulin sensitivity.
This investigation had a few limitations. In this study, fecal
bacteria loads were not determined after taking probiotic. Also, the
determination of gene expression related to biochemical proﬁles to
ﬁnd possible mechanisms is interesting.
Overall, our study proved that probiotic supplementation for 12
weeks by people with PD had useful impact on MDS-UPDRS, hs-
CRP, GSH, MDA, insulin metabolism, but unchanged other meta-
bolic proﬁles.Conﬂicts of interest
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